We also found that the MEK/ERK pathway is significantly activated in CRC cells treated with the p38α inhibitor SB202190, irrespective of the mutational status of the ERK upstream activators, RAS and RAF. This evidence concerns the gene MAP2K7 and colorectal carcinoma.